The US FDA granted Wockhardt’s new antibiotic, WCK 6777, Fast Track designation for the treatment of complicated urinary tract infections and intra-abdominal infections.
It successfully completed Phase I trials, with good safety results. WCK 6777 is a once-a-day -lactam enhancer antibiotic that is effective against drug-resistant pathogens and has outpatient treatment potential.
In the exchange filing, the company shared that WCK 6777 is the only once-a-day drug in the global antibiotic pipeline intended for outpatient parenteral antimicrobial therapy (OPAT) in ambulatory settings.
The statement further reads, “WCK 6777 is active against entire range of meropenem-resistant Gram negative pathogens generally encountered in community as well as hospital urinary tract infections (UTI) and intra-abdominal infections (IAI). Such a therapeutic option is expected to cut hospital admissions, facilitate early patient discharge and thus offer patient-centred care for MDR infections.”
